Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

GKOS

HoldHot Air

Glaukos Corporation · Healthcare · United States · $10.6B · Avg Vol: $149M/d

46
StockRank
Get insider-trade alerts
Q
43
V
21
M
76
P/E (TTM)
ROE
-26.0%
D/E
0.2x
Dividend %

COMPANY DESCRIPTION

Glaukos Corporation is an ophthalmic medical technology company dedicated to the development and commercialization of innovative surgical devices and pharmaceutical therapies for the treatment of glaucoma. The company is a pioneer and market leader in Minimally Invasive Glaucoma Surgery (MIGS), leveraging its proprietary iStent technology to establish a new treatment paradigm. Glaukos's competitive strength derives from its first-mover advantage, strong intellectual property, and focus on addressing unmet needs in ophthalmology.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue282.9M314.7M383.5M507.4M21.5%612.8M690.8M844.5M29.0%
EPS-2.09-2.78-2.77-3.28-3.26
Shares47.8M49.1M56.4M57.5M+20.4%59.0M
Debt382.5M383.7M103.4M103.9M-35.2%107.6M
Equity530.0M461.8M766.9M656.2M7.4%
Op CF-33.1M-57.8M-61.3M-14.8M
Inv CF44.8M14.1M47.8M-77.6M
Fin CF6.3M15.0M91.5M11.9M
Loading 1Y...
PRICE (1Y)+11.2%
162169176183190Jul 29Aug 19Sep 9
SMA 50SMA 200

Close
$179.79
RSI (14)
36.6
52W High
$191.62
From 52W High
0.9%

SCORE BREAKDOWN

Quality
43
ROIC
-24.0%27.6
ROE
-26.0%27.5
GP/Assets
54.3%89.0
Op. Margin
-8.5%28.1
FCF/Assets
n/mN/A
Piotroski
25.9
Int. Cover
-41.3x12.7
D/E Ratio
0.16x54.5
Current Ratio
5.04x72.4
Value
21
P/E (TTM)
N/A
EV/EBITDA
-277.8x25.0
P/FCF
n/mN/A
P/B
15.3x7.5
P/S
17.1x17.9
Div Yield
N/A
Momentum
76
52W High %
94%92.5
RS 6M
61%93.1
SMA 50/200
1.29x93.1
EPS Rev 4W
+0.5%43.8
EPS Rev 12W
+5.3%79.8
EPS Improve
+115%77.4
Q Growth
N/A

FUNDAMENTALS

Market Cap
$10.6B
P/E (Forward)
351.9x
Gross Margin
79.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GKOS are excluded.

TickerCompanyMkt CapStockRankSignal
GKOSGlaukos Corporation(you)$10.6B46Hold
PODDInsulet Corporation$10.1B48Hold
BRKRBruker Corporation$8.7B47Hold
PENPenumbra, Inc.$12.7B51Hold
BIOBio-Rad Laboratories, Inc.$10.4B70Buy
NEOGNeogen Corporation$2.5B46Hold
IRTCiRhythm Holdings, Inc.$4.0B34Sell
BFLYButterfly Network, Inc.$2.2B41Hold
AXGNAxogen, Inc.$2.8B57Hold
GEHCGE HealthCare Technologies Inc.$32.4B63Hold

Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%

Glaukos Corporation (GKOS): Stock Score Summary

Glaukos Corporation (GKOS) has a MoatMap StockRank of 46/100 based on Quality (43/100), Value (21/100), and Momentum (76/100) factor scores. The current signal is HOLD.

Glaukos Corporation is an ophthalmic medical technology company dedicated to the development and commercialization of innovative surgical devices and pharmaceutical therapies for the treatment of glaucoma. The company is a pioneer and market leader in Minimally Invasive Glaucoma Surgery (MIGS), leveraging its proprietary iStent technology to establish a new treatment paradigm. Glaukos's competitive strength derives from its first-mover advantage, strong intellectual property, and focus on addressing unmet needs in ophthalmology.

Key Financial Metrics

Price$179.79
Market Cap$10.6B
P/E (Forward)351.89
Price/Book15.31
Return on Equity-26.0%
Return on Invested Capital-24.0%
Debt/Equity0.16x
Gross Margin79.1%
Operating Margin-8.5%
Revenue Growth49.5%
Free Cash Flow$6M

Glaukos Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Glaukos Corporation’s (GKOS) StockRank?
MoatMap’s StockRank for Glaukos Corporation (GKOS) is 46/100, with a Hold signal. It is a composite of Quality (43), Value (21), and Momentum (76) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Glaukos Corporation have an economic moat?
Glaukos Corporation (GKOS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Glaukos Corporation a buy, hold, or sell?
MoatMap’s current signal for Glaukos Corporation (GKOS) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Glaukos Corporation in?
Glaukos Corporation (GKOS) operates in the Healthcare sector, specifically the Medical Devices industry (United States).